Adcock Ingram Integrated Report 2018

The South African private pharmaceutical market, as measured by IQVIA MAT June 2018, is worth R42.9 billion, with 7.1% value and 4.9% volume growth (including new products). Adcock Ingram holds a private market share of 9% in value and 21% in volume . Adcock Ingram at a glance The high-volume liquids facility situated in Clayville is a state-of-the-art, highly automated factory primarily producing liquids and effervescent formulations. The Critical Care facility situated in Aeroton produces intravenous fluids, blood bags, renal dialysis products and small- volume parenterals. The tablet and capsule facility located in Wadeville is focused primarily on the manufacturing of anti-retroviral medicines. Trading profit R866m (2017: R724m) Water usage (Kℓ) 271 318 (2017: 281 247) Carbon emissions ** 24.67 (2017: 28.26) ** (Scope 1 and 2) per full-time employee (tonnes). Energy usage (kWh) 50 379m (2017: 49 456m) Share price close 6 015c Low: 4 900c High: 7 200c Turnover R6 540m (2017: R5 936m) HEPS 387.7c (2017: 308.9c ) NATURAL CAPITAL FINANCIAL CAPITAL * INTELLECTUAL CAPITAL BANGALORE (JV facility) Capacity – Tablets and capsules: 3,5 BILLION UNITS Accreditations: Nigeria (NAFDAC), UK (MHRA), Ghana (FDB), Australia (TGA), Namibia (NMRC), South Africa (SAHPRA), Uganda (UNDA), France (ANSM), Zimbabwe (MCAZ), Tanzania (TFDA), Malawi (PMPB), and Kenya (PPB), Ethiopia (FMHACA) MANUFACTURED CAPITAL * Continuing operations ADCOCK INGRAM  Integrated Report 2018 2 ABOUT US